LJ001
LJ001 is a broad-spectrum and orally active antiviral agent. LJ001 exerts antiviral activities by binding to viral membranes. LJ001 inhibits TGEV and PDCoV infection. LJ001 decreases TGEV N and PDCoV N-protein expression[1][2].
Product Specifications
CAS Number
[851305-26-5]
UNSPSC
12352005
Hazard Statement
H302-H315-H319
Target
HCV; HIV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/lj001.html
Purity
98.09
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
S=C(N(CC=C)C/1=O)SC1=C/C(O2)=CC=C2C3=CC=CC=C3
Molecular Formula
C17H13NO2S2
Molecular Weight
327.42
Precautions
P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
References & Citations
[1]Zhang Y, et al. Rhodanine derivative LJ001 inhibits TGEV and PDCoV replication in vitro. Virus Res. 2020 Nov;289:198167.|[2]Wolf MC, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A. 2010 Feb 16;107 (7) :3157-62.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
